SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Aug 26 2009, 11:03 AM EST

Phase III Trial with BioAlliance’s Orofacial Herpes Therapy Shows Positive Trend

GEN News Highlights

BioAlliance Pharma reported positive preliminary results from a Phase III trial evaluating acyclovir Lauriad®, its mucooadhesive buccal tablet for the treatment of orofacial herpes. Compared with placebo, acyclovir Lauriad shortened the time from first prodromal symptoms to healing and reduced healing time for patients presenting with primary vesicular lesions.

A higher percentage of patients in the acyclovir Lauriad group also demonstrated abortive lesions (i.e., without vesicular lesion). The single-dose, placebo-controlled trial included 722 patients with recurrent orofacial herpes.

BioAlliance’s acyclovir Lauriad product is based on the same, patented mucoadhesive buccal tablet technology as Loramyc®, the company’s product for treating oropharyngeal candidiasis in immunocompromised patients. Loramyc has been approved in a number of European countries and just yesterday was sanctioned by the Swiss regulatory authorities. An FDA submission for Loramyc was also recently accepted.

Bioalliance is developing three additional products using the Lauriad® technology. These include fentanyl Lauriad, clonidine Lauriad, and corticosteroid Lauriad. In its annual report for 2008 the company said clinical trials with the three products could start during 2009.

 

♦♦♦
Related News
BioAlliance Gets Swiss Regulatory Okay for Oral Candidasis Drug (Aug. 25, 2009)
BioAlliance to Advance Immtech’s Pafuramidine in Europe for $3M Upfront (Dec. 5, 2007)
BioAlliance Pharma Establishes European Joint Venture with Spepharm (Mar. 8, 2007)

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR